vs
CareDx, Inc.（CDNA）与Doximity, Inc.（DOCS）财务数据对比。点击上方公司名可切换其他公司
Doximity, Inc.的季度营收约是CareDx, Inc.的1.6倍（$185.1M vs $117.7M），Doximity, Inc.净利率更高（33.3% vs 2.4%，领先30.9%），CareDx, Inc.同比增速更快（39.0% vs 9.8%），过去两年Doximity, Inc.的营收复合增速更高（25.2% vs 12.9%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
Doximity Inc成立于2010年，是面向医疗专业人士的线上社交服务平台，为平台会员提供精选医疗资讯、远程医疗工具，以及病例协作相关功能，助力医疗从业者高效交流信息、开展诊疗相关工作。
CDNA vs DOCS — 直观对比
营收规模更大
DOCS
是对方的1.6倍
$117.7M
营收增速更快
CDNA
高出29.2%
9.8%
净利率更高
DOCS
高出30.9%
2.4%
两年增速更快
DOCS
近两年复合增速
12.9%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $185.1M |
| 净利润 | $2.8M | $61.6M |
| 毛利率 | — | 89.9% |
| 营业利润率 | 1.0% | 38.9% |
| 净利率 | 2.4% | 33.3% |
| 营收同比 | 39.0% | 9.8% |
| 净利润同比 | — | -18.1% |
| 每股收益（稀释后） | $0.05 | $0.31 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNADOCS
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | $185.1M | ||
| Q3 25 | $100.1M | $168.5M | ||
| Q2 25 | $86.7M | $145.9M | ||
| Q1 25 | $84.7M | $138.3M | ||
| Q4 24 | $86.6M | $168.6M | ||
| Q3 24 | $82.9M | $136.8M | ||
| Q2 24 | $92.3M | $126.7M |
净利润CDNADOCS
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | $61.6M | ||
| Q3 25 | $1.7M | $62.1M | ||
| Q2 25 | $-8.6M | $53.3M | ||
| Q1 25 | $-10.4M | $62.5M | ||
| Q4 24 | $87.7M | $75.2M | ||
| Q3 24 | $-10.6M | $44.2M | ||
| Q2 24 | $-4.6M | $41.4M |
毛利率CDNADOCS
| Q1 26 | — | — | ||
| Q4 25 | — | 89.9% | ||
| Q3 25 | — | 90.3% | ||
| Q2 25 | — | 89.2% | ||
| Q1 25 | — | 89.5% | ||
| Q4 24 | — | 91.6% | ||
| Q3 24 | — | 90.0% | ||
| Q2 24 | — | 89.3% |
营业利润率CDNADOCS
| Q1 26 | 1.0% | — | ||
| Q4 25 | -5.6% | 38.9% | ||
| Q3 25 | -0.2% | 37.8% | ||
| Q2 25 | -12.8% | 37.4% | ||
| Q1 25 | -15.8% | 35.2% | ||
| Q4 24 | 97.5% | 47.4% | ||
| Q3 24 | -16.6% | 38.8% | ||
| Q2 24 | -7.9% | 36.4% |
净利率CDNADOCS
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | 33.3% | ||
| Q3 25 | 1.7% | 36.8% | ||
| Q2 25 | -9.9% | 36.5% | ||
| Q1 25 | -12.2% | 45.2% | ||
| Q4 24 | 101.3% | 44.6% | ||
| Q3 24 | -12.8% | 32.3% | ||
| Q2 24 | -5.0% | 32.7% |
每股收益（稀释后）CDNADOCS
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | $0.31 | ||
| Q3 25 | $0.03 | $0.31 | ||
| Q2 25 | $-0.16 | $0.27 | ||
| Q1 25 | $-0.19 | $0.31 | ||
| Q4 24 | $1.60 | $0.37 | ||
| Q3 24 | $-0.20 | $0.22 | ||
| Q2 24 | $-0.09 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $64.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $979.3M |
| 总资产 | $411.1M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDNADOCS
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | $64.8M | ||
| Q3 25 | $194.2M | $169.2M | ||
| Q2 25 | $186.3M | $137.3M | ||
| Q1 25 | $230.9M | $209.6M | ||
| Q4 24 | $260.7M | $165.3M | ||
| Q3 24 | $240.9M | $184.2M | ||
| Q2 24 | $228.9M | $111.4M |
总债务CDNADOCS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — |
股东权益CDNADOCS
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | $979.3M | ||
| Q3 25 | $311.1M | $1.1B | ||
| Q2 25 | $327.4M | $1.0B | ||
| Q1 25 | $379.3M | $1.1B | ||
| Q4 24 | $378.4M | $1.0B | ||
| Q3 24 | $273.2M | $961.2M | ||
| Q2 24 | $264.7M | $913.6M |
总资产CDNADOCS
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $1.2B | ||
| Q3 25 | $432.3M | $1.3B | ||
| Q2 25 | $444.3M | $1.2B | ||
| Q1 25 | $489.6M | $1.3B | ||
| Q4 24 | $491.1M | $1.2B | ||
| Q3 24 | $477.0M | $1.1B | ||
| Q2 24 | $466.8M | $1.1B |
负债/权益比CDNADOCS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $60.9M |
| 自由现金流经营现金流 - 资本支出 | $514.0K | — |
| 自由现金流率自由现金流/营收 | 0.4% | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 1.54× | 0.99× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CDNADOCS
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | $60.9M | ||
| Q3 25 | $37.4M | $93.9M | ||
| Q2 25 | $9.9M | $62.1M | ||
| Q1 25 | $-26.6M | $98.5M | ||
| Q4 24 | $21.9M | $65.2M | ||
| Q3 24 | $12.5M | $68.3M | ||
| Q2 24 | $18.9M | $41.2M |
自由现金流CDNADOCS
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
自由现金流率CDNADOCS
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
资本支出强度CDNADOCS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% |
现金转化率CDNADOCS
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | 0.99× | ||
| Q3 25 | 22.30× | 1.51× | ||
| Q2 25 | — | 1.16× | ||
| Q1 25 | — | 1.58× | ||
| Q4 24 | 0.25× | 0.87× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Financial Results Total | $85.0M | 72% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
| Other | $6.4M | 5% |
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
